Innovative Treatment Solutions Sequana Medical's proprietary alfapump and DSR systems offer advanced solutions for fluid overload management, addressing unmet needs in patients with liver disease, heart failure, and cancer who are unresponsive to conventional therapies.

Growing Market Presence The company's active participation in international conferences such as SIR EDGE 2025 and Portal Intervention Symposium indicates increasing visibility and interest in their treatments among key healthcare stakeholders, opening avenues for strategic partnerships and product adoption.

Strong Financial Backing Recent substantial financing rounds totaling over €24 million enhance Sequana Medical's capacity to scale operations, expand clinical trials, and accelerate market penetration, making their solutions more accessible to healthcare providers.

Expanding Clinical Evidence Frequent presentations and sponsorships at specialized medical events demonstrate ongoing validation and demonstration of their treatments’ efficacy, which can support sales efforts by showcasing clinical benefits to hospitals and clinics.

Targeted Disease Focus Focusing on complex conditions like drug-resistant fluid overload associated with liver disease, heart failure, and cancer presents opportunities to collaborate with specialists and healthcare systems seeking innovative management solutions for these high-need patient populations.